At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Hyaluronic Acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot Study of Influence of Hyaluronic Acid (HA) on Bacillus Calmette-Guérin (BCG) Local Side Effects
In Brief
A Phase 2 clinical trial evaluating Hyaluronic Acid and BCG (Immucist®) for Poisoning by BCG Vaccine. Completed, enrolled 30 participants.
Detailed Summary
The purpose of this study is to evaluate a possible role of intravesical Hyaluronic Acid in reducing local toxicity of Bacillus Calmette Guerin (BCG) used to treat bladder urothelial cell carcinoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPoisoning by BCG Vaccine
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
Primary CompletionAug 2012
First PostedAug 2014
TodayJul 2026
First PostedAug 4, 2014
Enrollment StartSep 1, 2011
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 11.9 years ago
Interventions
Hyaluronic Aciddrug
Add hyaluronic acid to BCG Treatment
BCG (Immucist®)drug
Usual BCG treatment